The stock of OncoCyte Corporation (NASDAQ:OCX) last traded at $0.25, down -10.71% from the previous session.
Data from the available sources indicates that OncoCyte Corporation (NASDAQ:OCX) is covered by 5 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $1.40 and a low of $0.40, we find $0.75. Given the previous closing price of $0.28, this indicates a potential upside of 167.86 percent. OCX stock price is now -37.15% away from the 50-day moving average and -63.04% away from the 200-day moving average. The market capitalization of the company currently stands at $32.00M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
In total, 3 analysts have assigned it a hold rating, and 2 have given it a buy rating. Brokers who have rated the stock have averaged $0.83 as their price target over the next twelve months.
, while ‘Stephens’ rates the stock as ‘Overweight’.
In other news, Arno Andrew, Director bought 250,000 shares of the company’s stock on Dec 23. The stock was bought for $87,875 at an average price of $0.35. Upon completion of the transaction, the Director now directly owns 532,049 shares in the company, valued at $0.13 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 23, Director Gutfreund John Peter bought 75,000 shares of the business’s stock. A total of $24,728 was incurred on buying the stock at an average price of $0.33. This leaves the insider owning 75,000 shares of the company worth $18750.0. Insiders disposed of 432,514 shares of company stock worth roughly $0.11 million over the past 1 year. A total of 1.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in OCX stock. A new stake in OncoCyte Corporation shares was purchased by SUSQUEHANNA INTERNATIONAL GROUP, LLP during the first quarter worth $16,000. TRI LOCUM PARTNERS LP invested $10,000 in shares of OCX during the first quarter. In the first quarter, MERIT FINANCIAL GROUP, LLC acquired a new stake in OncoCyte Corporation valued at approximately $8,000. RENAISSANCE TECHNOLOGIES LLC acquired a new stake in OCX for approximately $7,000. LEE DANNER & BASS INC purchased a new stake in OCX valued at around $7,000 in the second quarter. In total, there are 91 active investors with 59.70% ownership of the company’s stock.
With an opening price of $0.2780 on Tuesday morning, OncoCyte Corporation (NASDAQ: OCX) set off the trading day. During the past 12 months, OncoCyte Corporation has had a low of $0.24 and a high of $1.68. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.80, and a quick ratio of 2.80. The fifty day moving average price for OCX is $0.3961 and a two-hundred day moving average price translates $0.6728 for the stock.
The latest earnings results from OncoCyte Corporation (NASDAQ: OCX) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.08, beating analysts’ expectations of -$0.11 by 0.03. This compares to -$0.15 EPS in the same period last year. The company reported revenue of $1.02 million for the quarter, compared to $0.98 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 3.35 percent. For the current quarter, analysts expect OCX to generate $1.42M in revenue.
OncoCyte Corporation(OCX) Company Profile
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
